NYSE:MCK - McKesson Stock Price, Price Target & More

Get Started

$146.50 -2.42 (-1.63 %)

(As of 05/21/2018 04:00 PM ET)

Previous Close$148.92

Today's Range$146.13 - $149.48

52-Week Range$134.25 - $178.86

Volume1.53 million shs

Average Volume1.72 million shs

Market Capitalization$30.73 billion

P/E Ratio12.62

Dividend Yield0.90%

Beta1.31

About McKesson (NYSE:MCK)

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. The company operates in two segments, McKesson Distribution Solutions and McKesson Technology Solutions. The McKesson Distribution Solutions segment distributes branded and generic pharmaceutical drugs, and other healthcare-related products; and provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. This segment also provides specialty pharmaceutical solutions for pharmaceutical manufacturers; and medical-surgical supply distribution, logistics, and other services to healthcare providers. In addition, this segment operates retail pharmacy chains in Europe and Canada, as well as supports independent pharmacy networks in North America and Europe; and supplies integrated pharmacy management systems, automated dispensing systems, and related services to retail, outpatient, central fill, specialty, and mail order pharmacies. This segment serves retail national accounts, including national and regional chains, food/drug combinations, mail order pharmacies, and mass merchandisers; and institutional healthcare providers, such as hospitals, health systems, integrated delivery networks, and long-term care providers, as well as offers its services to pharmaceutical manufacturers. The McKesson Technology Solutions segment provides clinical, financial, and supply chain management solutions to healthcare organizations. McKesson Corporation was founded in 1833 and is headquartered in San Francisco, California.

Receive MCK News and Ratings via Email

Sign-up to receive the latest news and ratings for MCK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drugs, proprietaries, & sundries

Sub-IndustryHealth Care Distributors

SectorMedical

SymbolNYSE:MCK

CUSIP58155Q10

Webwww.mckesson.com

Phone415-983-8300

Debt

Debt-to-Equity Ratio0.63

Current Ratio1.07

Quick Ratio0.61

Price-To-Earnings

Trailing P/E Ratio12.62

Forward P/E Ratio11.55

P/E Growth1.37

Sales & Book Value

Annual Sales$198.53 billion

Price / Sales0.15

Cash Flow$17.6506 per share

Price / Cash8.30

Book Value$53.16 per share

Price / Book2.76

Profitability

EPS (Most Recent Fiscal Year)$11.61

Net Income$5.07 billion

Net Margins2.34%

Return on Equity22.98%

Return on Assets4.22%

Miscellaneous

Employees78,000

Outstanding Shares206,340,000

McKesson (NYSE:MCK) Frequently Asked Questions

What is McKesson's stock symbol?

McKesson trades on the New York Stock Exchange (NYSE) under the ticker symbol "MCK."

How often does McKesson pay dividends? What is the dividend yield for McKesson?

McKesson announced a quarterly dividend on Thursday, April 26th. Stockholders of record on Friday, June 1st will be given a dividend of $0.34 per share on Monday, July 2nd. This represents a $1.36 annualized dividend and a dividend yield of 0.93%. The ex-dividend date is Thursday, May 31st. View McKesson's Dividend History.

How will McKesson's stock buyback program work?

McKesson announced that its Board of Directors has initiated a stock buyback plan on Thursday, October 27th 2016, which allows the company to buyback $4,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase up to 114% of its stock through open market purchases. Stock buyback plans are often an indication that the company's board of directors believes its stock is undervalued.

How were McKesson's earnings last quarter?

McKesson (NYSE:MCK) announced its quarterly earnings results on Thursday, October, 26th. The company reported $3.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.78 by $0.50. The business had revenue of $52.06 billion for the quarter, compared to the consensus estimate of $51.69 billion. McKesson had a return on equity of 22.98% and a net margin of 2.34%. McKesson's revenue was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.94 earnings per share. View McKesson's Earnings History.

When is McKesson's next earnings date?

McKesson is scheduled to release their next quarterly earnings announcement on Thursday, May, 24th 2018. View Earnings Estimates for McKesson.

What guidance has McKesson issued on next quarter's earnings?

McKesson updated its FY19 earnings guidance on Wednesday, April, 25th. The company provided earnings per share guidance of $13.00 -13.80 for the period, compared to the Thomson Reuters consensus EPS estimate of $13.37. McKesson also updated its FY18 guidance to $12.50 -12.80 EPS.

What price target have analysts set for MCK?

15 brokerages have issued 12 month price objectives for McKesson's stock. Their predictions range from $130.00 to $205.00. On average, they anticipate McKesson's stock price to reach $176.0667 in the next twelve months. View Analyst Ratings for McKesson.

Who are some of McKesson's key competitors?

Some companies that are related to McKesson include AmerisourceBergen (ABC), Cardinal Health (CAH), Herbal Center (HLF), Nu Skin Enterprises (NUS), PetIQ (PETQ), Aceto (ACET), biOasis Technologies (BIOAF), Trxade Group (TRXD) and Medizone International (MZEI).

Who are McKesson's key executives?

McKesson's management team includes the folowing people:

Mr. John H. Hammergren, Chairman, CEO & Pres (Age 59)
Mr. Jorge L. Figueredo, Exec. VP of HR (Age 57)
Mr. Paul C. Julian, Exec. VP (Age 63)
Britt J. Vitalone, CFO & Exec. VP
Ms. Kathleen D. McElligott, Chief Technology Officer, Chief Information Officer and Exec. VP (Age 62)

Has McKesson been receiving favorable news coverage?

News stories about MCK stock have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. McKesson earned a news sentiment score of 0.12 on Accern's scale. They also assigned news articles about the company an impact score of 48.25 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are McKesson's major shareholders?

McKesson's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.60%), Massachusetts Financial Services Co. MA (3.37%), Boston Partners (1.96%), Pzena Investment Management LLC (1.28%), Northern Trust Corp (1.20%) and Kiltearn Partners LLP (0.93%). Company insiders that own McKesson stock include Erin M Lampert, James A Beer, John H Hammergren, Lori A Schechter, M Christine Jacobs, Marie L/Ca Knowles, Patrick Blake, Susan R Salka and Wayne A Budd. View Institutional Ownership Trends for McKesson.

Which major investors are selling McKesson stock?

MCK stock was sold by a variety of institutional investors in the last quarter, including Sentry Investments Corp., BlackRock Inc., Taylor Asset Management Inc., Legal & General Group Plc, OMERS ADMINISTRATION Corp, Swiss National Bank, River & Mercantile Asset Management LLP and Prudential Financial Inc.. Company insiders that have sold McKesson company stock in the last year include Erin M Lampert, John H Hammergren, M Christine Jacobs and Marie L/Ca Knowles. View Insider Buying and Selling for McKesson.

Which major investors are buying McKesson stock?

MCK stock was acquired by a variety of institutional investors in the last quarter, including Boston Partners, Swedbank, Natixis, Robeco Institutional Asset Management B.V., Wells Fargo & Company MN, Amundi Pioneer Asset Management Inc., Old Mutual Global Investors UK Ltd. and Kiltearn Partners LLP. Company insiders that have bought McKesson stock in the last two years include Lori A Schechter and Susan R Salka. View Insider Buying and Selling for McKesson.

How do I buy shares of McKesson?

Shares of MCK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is McKesson's stock price today?

One share of MCK stock can currently be purchased for approximately $146.50.

How big of a company is McKesson?

McKesson has a market capitalization of $30.73 billion and generates $198.53 billion in revenue each year. The company earns $5.07 billion in net income (profit) each year or $11.61 on an earnings per share basis. McKesson employs 78,000 workers across the globe.

How can I contact McKesson?

McKesson's mailing address is ONE POST ST, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-983-8300 or via email at [email protected]

MarketBeat Community Rating for McKesson (MCK)

Community Ranking:		3.3 out of 5 ( )
Outperform Votes:		707 (Vote Outperform)
Underperform Votes:		352 (Vote Underperform)
Total Votes:		1,059

MarketBeat's community ratings are surveys of what our community members think about McKesson and other stocks. Vote "Outperform" if you believe MCK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MCK will underperform the S&P 500 over the long term. You may vote once every thirty days.

McKesson (NYSE:MCK) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

15 Wall Street analysts have issued ratings and price targets for McKesson in the last 12 months. Their average twelve-month price target is $176.0667, suggesting that the stock has a possible upside of 20.18%. The high price target for MCK is $205.00 and the low price target for MCK is $130.00. There are currently 1 sell rating, 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Buy	Hold
Consensus Rating Score:	2.47	2.47	2.53	2.47
Ratings Breakdown:	1 Sell Rating(s) 6 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 6 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 5 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 6 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$176.0667	$176.0667	$177.7333	$172.7333
Price Target Upside:	20.18% upside	22.95% upside	6.89% upside	23.06% upside

McKesson (NYSE:MCK) Consensus Price Target History

Price Target History for McKesson (NYSE:MCK)

McKesson (NYSE:MCK) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/11/2018	Bank of America	Lower Price Target	Buy ➝ Buy	$179.00 ➝ $172.00	Low
3/8/2018	Barclays	Initiated Coverage	Equal Weight ➝ Equal Weight	$165.00	Medium
2/2/2018	Credit Suisse Group	Reiterated Rating	Sell	$130.00	High
2/2/2018	Mizuho	Lower Price Target	Neutral ➝ Neutral	$186.00 ➝ $179.00	High
1/24/2018	Jefferies Group	Upgrade	Hold ➝ Buy	$205.00	High
1/23/2018	Needham & Company LLC	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $180.00	Medium
1/17/2018	Robert W. Baird	Reiterated Rating	Buy	$200.00	Low
1/4/2018	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$179.00	Low
12/4/2017	Deutsche Bank	Initiated Coverage	Buy	$175.00	High
10/27/2017	Royal Bank of Canada	Reiterated Rating	Hold	$170.00	N/A
10/10/2017	Cowen	Upgrade	Market Perform ➝ Outperform	$176.00 ➝ $189.00	N/A
9/14/2017	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$184.00 ➝ $172.00	High
6/29/2017	Leerink Swann	Boost Price Target	Market Perform	$170.00	Medium
6/26/2017	UBS	Reiterated Rating	Neutral	$156.00 ➝ $166.00	N/A
5/23/2017	JPMorgan Chase	Upgrade	Neutral ➝ Overweight	$189.00	Medium
3/6/2017	Citigroup	Boost Price Target	Buy	$169.00 ➝ $175.00	N/A
1/18/2017	Avondale Partners	Upgrade	Market Perform ➝ Outperform	$157.00 ➝ $193.00	N/A
11/11/2016	Standpoint Research	Downgrade	Buy ➝ Hold		N/A
9/19/2016	Argus	Reiterated Rating	Hold		N/A
9/16/2016	Goldman Sachs	Downgrade	Buy ➝ Neutral	$210.00 ➝ $189.00	N/A
6/29/2016	FBR & Co	Reiterated Rating	Buy	$210.00	N/A
6/1/2016	Raymond James	Downgrade	Strong-Buy ➝ Outperform		N/A

(Data available from 5/21/2016 forward)

McKesson (NYSE:MCK) Earnings History and Estimates Chart

Earnings by Quarter for McKesson (NYSE:MCK)

McKesson (NYSE:MCK) Earnings Estimates

2018 EPS Consensus Estimate: $12.24
2019 EPS Consensus Estimate: $12.89

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$2.85	$2.88	$2.87
Q2 2018	2	$2.80	$2.82	$2.81
Q3 2018	2	$2.90	$2.91	$2.91
Q4 2018	2	$3.54	$3.78	$3.66
Q1 2019	1	$2.82	$2.82	$2.82
Q2 2019	1	$3.01	$3.01	$3.01
Q3 2019	1	$3.24	$3.24	$3.24
Q4 2019	1	$3.82	$3.82	$3.82

McKesson (NYSE MCK) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/24/2018		$3.54					N/A
2/1/2018	Q3 2018	$2.92	$3.41	$51.9809 billion	$53.6170 billion	View	N/A
10/26/2017	Q2 2018	$2.78	$3.28	$51.6944 billion	$52.0610 billion	View	N/A
7/27/2017	Q1 2018	$2.81	$2.46	$51.2185 billion	$51.0510 billion	View	N/A
5/18/2017	Q4 17	$3.04	$3.39	$49.4824 billion	$48.7130 billion	View	N/A
1/25/2017	Q317	$2.95	$3.03	$50.71 billion	$50.13 billion	View	N/A
10/27/2016	Q217	$3.05	$2.94	$24.16 billion	$49.9570 billion	View	Listen
7/27/2016	Q117	$3.33	$3.50	$50.32 billion	$49.7330 billion	View	Listen
5/4/2016	Q416	$3.14	$2.44	$46.83 billion	$46.6780 billion	View	N/A
1/27/2016	Q316	$3.13	$3.18	$48.97 billion	$47.8990 billion	View	Listen
10/29/2015	Q216	$2.99	$3.31	$47.85 billion	$48.60 billion	View	Listen
7/29/2015	Q116	$2.89	$3.14	$46.02 billion	$47.50 billion	View	Listen
5/12/2015	Q415	$2.75	$2.94	$45.00 billion	$44.9250 billion	View	Listen
2/5/2015	Q315	$2.61	$2.89	$44.81 billion	$47.0050 billion	View	N/A
10/28/2014	Q215	$2.73	$2.79	$42.99 billion	$44.76 billion	View	N/A
7/31/2014	Q115	$2.34	$2.49	$40.65 billion	$44.06 billion	View	N/A
5/12/2014	Q414	$2.40	$2.55	$35.89 billion	$38.14 billion	View	N/A
1/31/2014	Q314	$1.85	$1.45	$38.57 billion	$34.30 billion	View	N/A
10/24/2013	Q214	$2.03	$2.27	$32.16 billion	$33.00 billion	View	Listen
7/25/2013	Q1 2014	$1.71	$2.07	$32.60 billion	$32.20 billion	View	Listen
5/7/2013	Q4 2013	$2.30	$1.45	$32.01 billion	$30.62 billion	View	Listen
1/31/2013	Q3 2013	$1.62	$1.41	$30.81 billion	$31.1870 billion	View	Listen
10/25/2012		$1.78	$1.92			View	N/A
7/26/2012		$1.48	$1.55			View	N/A
4/30/2012		$2.04	$2.09			View	N/A
1/30/2012		$1.38	$1.40			View	N/A
10/25/2011		$1.38	$1.63			View	N/A
7/28/2011		$1.10	$1.27			View	N/A
5/3/2011		$1.60	$1.66			View	N/A
1/31/2011		$1.12	$1.12			View	N/A
10/26/2010	Q2 2011	$1.09	$1.03			View	N/A
7/30/2010	Q1 2011	$1.07	$1.10			View	N/A
5/3/2010	Q4 2010	$1.29	$1.27			View	N/A
1/26/2010	Q3 2010	$1.19	$1.19			View	N/A
10/27/2009	Q2 2010	$1.01	$1.07			View	N/A
7/28/2009	Q1 2010	$0.86	$1.06			View	N/A
5/4/2009	Q4 2009	$1.15	$1.23			View	N/A
1/26/2009	Q3 2009	$0.86	$1.05			View	N/A
10/28/2008	Q2 2009	$1.02	$1.17			View	N/A
7/23/2008	Q1 2009	$0.80	$0.83			View	N/A
5/5/2008	Q4 2008	$1.00	$1.05			View	N/A
1/31/2008	Q3 2008	$0.80	$0.79			View	N/A

(Earnings results data provided by Zacks Investment Research)

McKesson (NYSE:MCK) Dividend Information

McKesson pays an annual dividend of $1.36 per share, with a dividend yield of 0.93%. MCK's next quarterly dividend payment will be made on Monday, July 2. The company has grown its dividend for the last 5 consecutive years and is increasing its dividend by an average of 7.10% each year. McKesson pays out 11.71% of its earnings out as a dividend.

Next Dividend:	7/2/2018
Annual Dividend:	$1.36
Dividend Yield:	0.93%
Dividend Growth:	7.10% (3 Year Average)
Payout Ratio(s):	11.71% (Trailing 12 Months of Earnings) 10.73% (Based on This Year's Estimates) 10.16% (Based on Next Year's Estimates) 7.71% (Based on Cash Flow)
Track Record:	5 Years of Consecutive Dividend Growth
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for McKesson (NYSE:MCK)

McKesson (NYSE:MCK) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/26/2018	quarterly	$0.34	0.88%	5/31/2018	6/1/2018	7/2/2018
2/1/2018	quarterly	$0.34	0.97%	2/28/2018	3/1/2018	4/2/2018
10/26/2017	quarterly	$0.34	1%	11/30/2017	12/1/2017	1/2/2018
7/26/2017	quarterly	$0.34	0.84%	8/30/2017	9/1/2017	10/2/2017
5/24/2017	quarterly	$0.28	0.69%	6/1/2017	6/5/2017	7/3/2017
1/25/2017	quarterly	$0.28	0.81%	2/27/2017	3/1/2017	4/3/2017
10/27/2016	quarterly	$0.28	0.9%	11/29/2016	12/1/2016	1/2/2017
7/26/2016	quarterly	$0.28	0.57%	8/30/2016	9/1/2016	10/3/2016
5/25/2016	quarterly	$0.28	0.62%	6/2/2016	6/6/2016	7/1/2016
1/27/2016	quarterly	$0.28	0.7%	2/26/2016	3/1/2016	4/1/2016
10/30/2015	quarterly	$0.28	0.62%	11/27/2015	12/1/2015	1/4/2016
7/29/2015	quarterly	$0.28	0.52%	8/28/2015	9/1/2015	10/1/2015
5/27/2015	quarterly	$0.24	0.4%	6/4/2015	6/8/2015	7/1/2015
1/29/2015	quarterly	$0.24	0.44%	2/26/2015	3/2/2015	4/1/2015
10/21/2014	quarterly	$0.24	0.49%	11/26/2014	12/1/2014	1/2/2015
7/30/2014	quarterly	$0.24	0.49%	8/28/2014	9/2/2014	10/1/2014
5/28/2014	quarterly	$0.24	0.51%	6/5/2014	6/9/2014	7/1/2014
1/29/2014	quarterly	$0.24	0.54%	2/27/2014	3/3/2014	4/1/2014
10/25/2013	quarterly	$0.24	0.63%	11/27/2013	12/2/2013	1/2/2014
7/25/2013	quarterly	$0.24	0.77%	8/29/2013	9/3/2013	10/1/2013
5/22/2013	quarterly	$0.22	0.68%	6/5/2013	6/7/2013	7/1/2013
1/30/2013	quarterly	$0.20	0.76%	2/27/2013	3/1/2013	4/1/2013

(Data available from 1/1/2013 forward)

McKesson (NYSE MCK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.20%
Institutional Ownership Percentage: 88.37%

Insider Trading History for McKesson (NYSE:MCK)

Institutional Ownership by Quarter for McKesson (NYSE:MCK)

McKesson (NYSE MCK) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/1/2018	Erin M. Lampert	SVP	Sell	1,413	$149.38	$211,073.94
12/14/2017	John H. Hammergren	Chairman	Sell	65,000	$160.00	$10,400,000.00
9/29/2017	John H Hammergren	CEO	Sell	99,000	$153.89	$15,235,110.00	165,000
9/28/2017	John H Hammergren	CEO	Sell	100,000	$153.51	$15,351,000.00	165,000
9/27/2017	John H Hammergren	CEO	Sell	100,000	$155.30	$15,530,000.00	165,000
9/26/2017	John H Hammergren	CEO	Sell	100,000	$154.81	$15,481,000.00	165,000
9/25/2017	John H Hammergren	CEO	Sell	100,000	$154.15	$15,415,000.00	165,000
9/22/2017	John H. Hammergren	Chairman	Sell	225,000	$151.67	$34,125,750.00
9/22/2017	John H. Hammergren	CEO	Sell	100,000	$153.53	$15,353,000.00
9/20/2017	John H. Hammergren	CEO	Sell	125,000	$150.18	$18,772,500.00
9/7/2017	Erin M. Lampert	SVP	Sell	900	$155.65	$140,085.00
8/21/2017	M Christine Jacobs	Director	Sell	1,083	$145.43	$157,500.69
7/31/2017	Marie L/Ca Knowles	Director	Sell	1,083	$162.55	$176,041.65
6/1/2017	John H Hammergren	Chairman	Sell	38,619	$163.76	$6,324,247.44	19,309
5/31/2017	Erin M Lampert	SVP	Sell	809	$160.66	$129,973.94	59
5/30/2017	Erin M Lampert	SVP	Sell	404	$160.53	$64,854.12	2,003
5/30/2017	John H Hammergren	Chairman	Sell	19,316	$162.31	$3,135,179.96	96,644
3/29/2017	John H Hammergren	Chairman	Sell	100,500	$150.44	$15,119,220.00	22,390
3/2/2017	John H Hammergren	Chairman	Sell	100,500	$150.49	$15,124,245.00	57,900
12/5/2016	Wayne A. Budd	Director	Sell	723	$145.77	$105,391.71
11/30/2016	Lori A Schechter	EVP	Buy	692	$144.52	$100,007.84
11/2/2016	Susan R Salka	Director	Buy	1,000	$136.35	$136,350.00
10/31/2016	Erin M Lampert	SVP	Sell	921	$123.99	$114,194.79	1,765
10/3/2016	Erin M. Lampert	SVP	Sell	1,739	$165.94	$288,569.66
9/12/2016	John H Hammergren	Chairman	Sell	100,500	$180.77	$18,167,385.00	100,500
9/12/2016	Wayne A Budd	Director	Sell	2,309	$179.70	$414,927.30	723
9/6/2016	John H Hammergren	Chairman	Sell	100,500	$184.22	$18,514,110.00	100,500
8/22/2016	M Christine Jacobs	Director	Sell	915	$193.78	$177,308.70
8/1/2016	Marie L/Ca Knowles	Director	Sell	915	$192.73	$176,347.95
7/14/2016	James A Beer	CFO	Sell	5,500	$199.00	$1,094,500.00	12,412
5/25/2016	John H Hammergren	CEO	Sell	37,420	$182.87	$6,842,995.40	18,711
5/25/2016	Patrick Blake	EVP	Sell	6,322	$182.87	$1,156,104.14	5,328
5/24/2016	John H Hammergren	CEO	Sell	18,709	$182.06	$3,406,160.54	18,711
5/24/2016	Lori A Schechter	EVP	Sell	107	$182.06	$19,480.42	6,259
5/23/2016	John H Hammergren	CEO	Sell	18,718	$179.33	$3,356,698.94	94,000
5/23/2016	Patrick Blake	EVP	Sell	3,162	$179.33	$567,041.46	20,167
5/10/2016	John H Hammergren	CEO	Sell	101,833	$170.71	$17,383,911.43	101,833
4/25/2016	John H Hammergren	CEO	Sell	101,833	$176.81	$18,005,092.73	101,833
4/4/2016	John H Hammergren	CEO	Sell	45,300	$159.00	$7,202,700.00	45,300
3/15/2016	Nigel A Rees	SVP	Sell	6,000	$157.59	$945,540.00	11,000
2/2/2016	Susan R Salka	Director	Buy	1,000	$156.21	$156,210.00
2/1/2016	Lori A. Schechter	EVP	Sell	2,476	$159.73	$395,491.48
1/4/2016	John H. Hammergren	CEO	Sell	101,833	$194.11	$19,766,803.63
12/1/2015	John H. Hammergren	CEO	Sell	101,833	$190.06	$19,354,379.98
11/24/2015	John H. Hammergren	CEO	Sell	56,533	$190.01	$10,741,835.33
10/12/2015	John H. Hammergren	CEO	Sell	101,835	$190.51	$19,400,585.85
8/13/2015	Paul C Julian	EVP	Sell	55,666	$214.54	$11,942,583.64
7/15/2015	Paul C Julian	EVP	Sell	27,833	$234.04	$6,514,035.32
7/14/2015	Paul C Julian	EVP	Sell	27,833	$232.86	$6,481,192.38
6/17/2015	Paul C Julian	EVP	Sell	55,668	$234.06	$13,029,652.08
5/28/2015	John H Hammergren	CEO	Sell	60,000	$238.53	$14,311,800.00
5/28/2015	Lori A Schechter	EVP	Sell	1,468	$238.22	$349,706.96
5/26/2015	John H Hammergren	CEO	Sell	30,062	$238.97	$7,183,916.14
5/26/2015	Paul C Julian	EVP	Sell	15,289	$238.97	$3,653,612.33
5/22/2015	Jorge Figueredo	EVP	Sell	20,775	$240.11	$4,988,285.25
5/15/2015	Jorge Figueredo	EVP	Sell	8,525	$240.00	$2,046,000.00
2/17/2015	Randall N Spratt	EVP	Sell	44,523	$225.00	$10,017,675.00
2/12/2015	Randall N Spratt	EVP	Sell	7,477	$225.00	$1,682,325.00
2/10/2015	Alton F Irby III	Director	Sell	5,000	$220.76	$1,103,800.00
2/10/2015	Nigel A Rees	Major Shareholder	Sell	9,000	$220.42	$1,983,780.00
1/28/2015	John H Hammergren	CEO	Sell	64,521	$219.52	$14,163,649.92
1/26/2015	Brian Scott Tyler	EVP	Sell	5,431	$216.62	$1,176,463.22
1/26/2015	John H Hammergren	CEO	Sell	35,479	$219.07	$7,772,384.53
1/7/2015	John H Hammergren	CEO	Sell	77,100	$214.00	$16,499,400.00
12/8/2014	John H Hammergren	CEO	Sell	12,200	$214.01	$2,610,922.00
11/28/2014	Patrick Blake	EVP	Sell	19,000	$210.00	$3,990,000.00
11/24/2014	John H Hammergren	CEO	Sell	100,000	$209.25	$20,925,000.00
11/12/2014	Paul C Julian	EVP	Sell	74,666	$202.51	$15,120,611.66
10/31/2014	Patrick Blake	EVP	Sell	38,000	$204.68	$7,777,840.00
10/8/2014	Paul C Julian	EVP	Sell	74,667	$195.86	$14,624,278.62
10/7/2014	John H Hammergren	CEO	Sell	100,000	$197.28	$19,728,000.00
9/10/2014	Paul C Julian	EVP	Sell	74,667	$196.76	$14,691,478.92
8/29/2014	Jorge Figueredo	EVP	Sell	24,500	$195.00	$4,777,500.00
8/8/2014	M Christine Jacobs	Director	Sell	2,619	$189.88	$497,295.72
8/5/2014	Marie L/Ca Knowles	Director	Sell	785	$192.10	$150,798.50
6/2/2014	Patrick Blake	EVP	Sell	15,000	$190.00	$2,850,000.00
5/29/2014	Paul C Julian	EVP	Sell	21,057	$186.89	$3,935,342.73
5/28/2014	Alton F Irby III	Director	Sell	4,000	$182.73	$730,920.00
5/28/2014	John H Hammergren	CEO	Sell	125,596	$183.31	$23,023,002.76
5/28/2014	Jorge Figueredo	EVP	Sell	20,542	$183.30	$3,765,348.60
5/27/2014	Brian Scott Tyler	EVP	Sell	3,916	$183.30	$717,802.80
5/22/2014	Brian Scott Tyler	EVP	Sell	8,250	$184.17	$1,519,402.50	5
3/21/2014	Jorge Figueredo	EVP	Sell	23,684	$185.81	$4,400,724.04
3/10/2014	Patrick Blake	EVP	Sell	38,750	$180.36	$6,988,950.00	1,827
2/4/2014	Brian Scott Tyler	EVP	Sell	6,250	$169.68	$1,060,500.00	5
1/22/2014	Alton Irby III	Director	Sell	1,300	$167.98	$218,374.00	25,599
11/1/2013	Nigel A Rees	CFO	Sell	7,000	$158.72	$1,111,040.00
10/29/2013	Brian Scott Tyler	EVP	Sell	8,250	$153.44	$1,265,880.00
10/11/2013	Brian Scott Tyler	EVP	Sell	9,000	$138.51	$1,246,590.00	5
10/9/2013	Paul Julian	EVP	Sell	84,000	$134.04	$11,259,360.00	57
10/8/2013	Brian Scott Tyler	EVP	Sell	9,000	$138.00	$1,242,000.00	5
9/11/2013	Paul C Julian	EVP	Sell	84,000	$126.20	$10,600,800.00
8/7/2013	Paul Julian	EVP	Sell	84,000	$123.29	$10,356,360.00	57
8/6/2013	Marie L/Ca Knowles	Director	Sell	1,223	$123.54	$151,089.42
7/30/2013	Brian Scott Tyler	EVP	Sell	6,250	$123.94	$774,625.00
6/19/2013	Paul C Julian	EVP	Sell	84,750	$114.89	$9,736,927.50
6/14/2013	David M Lawrence	Director	Sell	7,500	$114.28	$857,100.00
6/14/2013	Jorge Figueredo	EVP	Sell	6,250	$115.00	$718,750.00
6/10/2013	Jorge Figueredo	EVP	Sell	10,000	$115.00	$1,150,000.00
6/4/2013	Jorge Figueredo	EVP	Sell	22,500	$113.63	$2,556,675.00
5/30/2013	Laureen Seeger	EVP	Sell	57,750	$114.89	$6,634,897.50
5/29/2013	John H Hammergren	CEO	Sell	230,484	$115.21	$26,554,061.64
5/29/2013	Randall N Spratt	EVP	Sell	32,226	$115.21	$3,712,757.46
5/28/2013	Brian Scott Tyler	EVP	Sell	6,023	$116.33	$700,655.59
5/28/2013	Jeffrey C Campbell	CFO	Sell	73,102	$116.33	$8,503,955.66
5/24/2013	Laureen Seeger	EVP	Sell	17,250	$116.50	$2,009,625.00
5/22/2013	Laureen Seeger	EVP	Sell	17,250	$118.13	$2,037,742.50
5/20/2013	Brian Scott Tyler	EVP	Sell	5,000	$117.81	$589,050.00
5/15/2013	Nigel A Rees	VP	Sell	8,000	$116.00	$928,000.00
5/10/2013	Brian Scott Tyler	EVP	Sell	6,250	$115.59	$722,437.50
5/10/2013	John H Hammergren	CEO	Sell	75,000	$115.30	$8,647,500.00
1/18/2013	Jorge Figueredo	EVP	Sell	2,500	$103.22	$258,050.00
1/17/2013	Laureen Seeger	EVP	Sell	17,250	$103.00	$1,776,750.00
9/4/2012	Paul C Julian	EVP	Sell	36,250	$87.02	$3,154,475.00

(Data available from 1/1/2013 forward)

McKesson (NYSE MCK) News Headlines

Source:

Date	Headline
	Investors have shrugged off Trump drug price plan, but it could be early finance.yahoo.com - May 21 at 8:30 AM
	Spend it like Buffett: McKesson's stock is trading close to the 52-week low www.theglobeandmail.com - May 20 at 5:43 PM
	Critical Review: McKesson (MCK) & Trxade Group (TRXD) www.americanbankingnews.com - May 20 at 5:24 AM
	Herbal Center (HLF) & McKesson (MCK) Head-To-Head Survey www.americanbankingnews.com - May 17 at 3:23 PM
	McKesson (MCK) to Release Earnings on Thursday www.americanbankingnews.com - May 17 at 1:16 AM
	Real-World Evidence from McKesson Supports First-Ever FDA Approval for Metastatic Merkel Cell Carcinoma Drug www.businesswire.com - May 16 at 5:40 PM
	Will Core Distribution Unit Aid McKesson (MCK) Q4 Earnings? www.zacks.com - May 16 at 8:46 AM
	McKesson Board Can't Dodge Opioid Shipment `Red Flags' Suit finance.yahoo.com - May 16 at 8:46 AM
	Rite Aid (RAD)/Albertsons More Likely to Depart McKesson (MCK), a Positive for AmerisourceBergen (ABC) - RBC www.streetinsider.com - May 15 at 5:32 PM
	$51.58 Billion in Sales Expected for McKesson (MCK) This Quarter www.americanbankingnews.com - May 15 at 5:03 AM
	McKesson (MCK) Expected to Announce Earnings of $3.54 Per Share www.americanbankingnews.com - May 13 at 1:22 AM
	Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology ... globenewswire.com - May 11 at 9:02 AM
	McKesson (MCK) Set to Announce Quarterly Earnings on Wednesday www.americanbankingnews.com - May 9 at 1:16 AM
	McKesson ideaShare: The Independent's Power to Perform www.businesswire.com - May 7 at 5:34 PM
	McKesson To Acquire MSD For Medical Supply Distribution seekingalpha.com - May 7 at 5:34 PM
	Former McKesson VP David Nace MD Joins Leading Healthcare Data Platform Company Innovaccer as Chief Medical Officer www.prnewswire.com - May 3 at 11:58 AM
	Critical Comparison: McKesson (MCK) versus PetIQ (PETQ) www.americanbankingnews.com - May 2 at 10:31 AM
	Head to Head Contrast: Nu Skin Enterprises (NUS) vs. McKesson (MCK) www.americanbankingnews.com - May 2 at 1:24 AM
	McKesson (MCK) Receives Average Recommendation of "Hold" from Analysts www.americanbankingnews.com - April 30 at 3:40 PM
	Form 8-K MCKESSON CORP For: Apr 24 www.streetinsider.com - April 30 at 9:31 AM
	McKesson Board of Directors Elects Brad Lerman as New Independent Director finance.yahoo.com - April 30 at 9:31 AM
	McKesson Corporation Fiscal 2018 Fourth Quarter Conference Call Scheduled for May 24, 2018 finance.yahoo.com - April 30 at 9:31 AM
	Rexall to shutter some stores as pharmacy market faces pressure www.theglobeandmail.com - April 27 at 5:28 PM
	McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids finance.yahoo.com - April 27 at 8:05 AM
	Analysts Expect McKesson (MCK) Will Announce Quarterly Sales of $51.58 Billion www.americanbankingnews.com - April 27 at 3:00 AM
	McKesson Announces Quarterly Dividend of $0.34 (MCK) www.americanbankingnews.com - April 26 at 6:10 PM
	[$$] McKesson Launches Comprehensive Review of Operations finance.yahoo.com - April 26 at 5:28 PM
	McKesson (MCK) Releases FY18 Earnings Guidance www.americanbankingnews.com - April 25 at 5:50 PM
	McKesson (MCK) Updates FY19 Earnings Guidance www.americanbankingnews.com - April 25 at 5:50 PM
	BRIEF-McKesson Launches Multi-Year Strategic Growth Initiative; Reaffirms Fiscal 2018 Outlook www.reuters.com - April 25 at 5:29 PM
	McKesson (MCK) to Acquire MSD for $800M; Reaffirms Fiscal 2018 Outlook and Provides Preliminary Fiscal 2019 ... www.streetinsider.com - April 25 at 5:29 PM
	McKesson Launches Multi-Year Strategic Growth Initiative; Reaffirms Fiscal 2018 Outlook and Provides Preliminary Fiscal 2019 Outlook finance.yahoo.com - April 25 at 5:29 PM
	McKesson (MCK) Expected to Post Earnings of $3.54 Per Share www.americanbankingnews.com - April 25 at 1:24 PM
	PolarityTE (COOL) Names Willie Bogan to Board www.streetinsider.com - April 25 at 8:27 AM
	BRIEF-Polarityte Announces Appointment Of Mckesson'S Willie Bogan To Board Of Directors www.reuters.com - April 24 at 5:29 PM
	McKesson's Board Clears Itself of Fault on Opioid Oversight www.bloomberg.com - April 24 at 8:04 AM
	Glenview's Robbins pitches Long on Express Scripts (ESRX), McKesson (MCK), and CVS Health (CVS) at Sohn; Says ... www.streetinsider.com - April 23 at 5:25 PM
	McKesson's Board Clears Itself of Wrongdoing on Opioid Oversight finance.yahoo.com - April 23 at 5:25 PM
	PetIQ (PETQ) and McKesson (MCK) Financial Review www.americanbankingnews.com - April 21 at 11:14 AM
	McKesson (MCK) Upgraded at Vetr www.americanbankingnews.com - April 20 at 9:12 PM
	McKesson (MCK) Given "Neutral" Rating at UBS www.americanbankingnews.com - April 20 at 5:52 PM
	Earns New Patent for Proprietary Inventory Management Technology www.businesswire.com - April 20 at 5:37 PM
	McKesson (MCK) Lifted to "Buy" at Zacks Investment Research www.americanbankingnews.com - April 18 at 8:00 PM
	Vetr Lowers McKesson (MCK) to Buy www.americanbankingnews.com - April 18 at 12:16 PM
	McKesson Is Undervalued seekingalpha.com - April 16 at 9:08 AM
	McKesson (MCK) Lowered to Hold at BidaskClub www.americanbankingnews.com - April 14 at 10:19 PM
	Congress Sets Opioid Hearing Next Month for Drug Distributors finance.yahoo.com - April 13 at 5:34 PM
	Want To Invest In McKesson Corporation (NYSE:MCK)? Here’s How It Performed Lately finance.yahoo.com - April 13 at 8:26 AM
	Contrasting Nu Skin Enterprises (NUS) & McKesson (MCK) www.americanbankingnews.com - April 13 at 5:07 AM
	McKesson (MCK) PT Lowered to $172 at BofA/Merrill Lynch www.streetinsider.com - April 12 at 8:37 AM

McKesson (NYSE:MCK) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

McKesson (NYSE:MCK) Income Statement, Balance Sheet and Cash Flow Statement

McKesson (NYSE MCK) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff